Yvette Stallwood, J Proteomics Bioinform 2017, 10:10 (Suppl)
DOI: 10.4172/0974-276X-C1-103

Predicting, avoiding and mitigating risk of failure when developing biotherapeutics

Yvette Stallwood
Lonza Biologics, UK

This presentation will discuss how *in silico* and *in vitro* methodologies are employed to perform a developability and immunogenicity risk assessment in order to highlight potential risks of failure for the development of biotherapeutics. *In silico* methods can be used to evaluate protein sequence and structure to assess the likelihood of immunogenic responses and potential manufacturability issues including aggregation and PTMs. *Ex vivo* T and B-Cell responses enable the assessment of overall immunogenicity risks; different approaches are highlighted to further identify processed and presented epitopes.

Biography

Yvette Stallwood has completed her PhD at the University of Birmingham (UK) and joined Lonza in 2007. She has been Head of Applied Protein Services for five years. The Applied Protein Services team are focussed on the development and provision of services to support the development of new biotherapeutic proteins with a particular focus on immunogenicity and manufacturability.

yvette.stallwood@lonza.com

Notes: